Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$541.55M, compared with -$462.88M a year earlier.
Context
- Retained earnings amounted to 220.7% of total assets at the end of Q1 FY2026, up 81.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -17.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (514.59M) USD
- Year-over-year change
- -14.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (514.59M) | -14.7% |
| FY2024 | 2024-12-31 | (448.81M) | -22.0% |
| FY2023 | 2023-12-31 | (367.87M) | -8.8% |
| FY2022 | 2022-12-31 | (338.14M) | +2.7% |
| FY2021 | 2021-12-31 | (347.49M) | — |
Retained Earnings vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -17.0% is the 6th highest of 11, against a peer median of -19.7%.
- Retained earnings amounts to 220.7% of total assets for ARCT, versus a peer median of 437.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$260.91M USD | -23.1% | — | 139.5% | |
| Mar 2026 | -€479.39M EUR | -1.7% | — | 483.6% | |
| Mar 2026 | -$541.55M USD | -17.0% | — | 220.7% | |
| Mar 2026 | -$568.01M USD | -42.5% | — | 212.7% | |
| Mar 2026 | -$577.53M USD | -214.9% | — | 501.7% | |
| Mar 2026 | -€711.94M EUR | -24.2% | — | 191.2% | |
| Mar 2026 | -$1.21B USD | +11.7% | — | 436.7% | |
| Mar 2026 | -$1.32B USD | -50.3% | — | 129.0% | |
| Mar 2026 | -$1.49B USD | -16.4% | — | 521.7% | |
| Mar 2026 | -$1.83B USD | -4.9% | — | 3686.1% | |
| Mar 2026 | -$4.58B USD | -2.0% | — | 438.8% | |
| Peer median (excluding ARCT) | — | -19.7% | — | 437.8% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 370.49M | 391.88M | 292.01M | 237.03M | 230.91M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.37M | 2.76M | 32.06M | 3.97M | 5.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.69M | 55M | 64.98M | 4.97M |
| Total Current Assets | 378.96M | 403.33M | 386.59M | 305.98M | 241.45M |
| Property, Plant & Equipment (Net) | 11.26M | 44.96M | 40.93M | 36.21M | 27.82M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 515K | 0 | 1.89M | 0 | 1.89M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.08M | 2.09M | 0 | 1.89M | 0 |
| Total Non-current Assets | 13.85M | 47.05M | 42.81M | 38.09M | 29.7M |
| Total Assets | 392.81M | 450.39M | 429.4M | 344.07M | 271.15M |
| Account Payables | 10.06M | 7.45M | 5.28M | 7.19M | 4.24M |
| Short-term Debt | 22.47M | 60.66M | 0 | 0 | 0 |
| Tax Payables | 0 | 1.3M | 641K | 0 | 0 |
| Deferred Revenue | 43.48M | 36.12M | 47.34M | 21.94M | 8.25M |
| Other Current Liabilities | 3.58M | 4.04M | 18.5M | 13.31M | 6.95M |
| Total Current Liabilities | 99.54M | 126.98M | 81.99M | 65.49M | 36.38M |
| Long-term Debt | 40.63M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 20.07M | 42.5M | 12.6M | 0 |
| Other Non-current Liabilities | 19.93M | 2.8M | 497K | 0 | 0 |
| Total Non-current Liabilities | 65.07M | 53.09M | 68.9M | 37.6M | 20.78M |
| Total Liabilities | 164.6M | 180.08M | 150.89M | 103.09M | 57.16M |
| Common Stock | 26K | 27K | 27K | 27K | 28K |
| Retained Earnings | (347.49M) | (338.14M) | (367.87M) | (448.81M) | (514.59M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 228.21M | 270.31M | 278.51M | 240.98M | 213.99M |
| Total Debt | 69.15M | 94.76M | 30.22M | 28.55M | 25M |
| Net Debt | (301.35M) | (297.13M) | (261.79M) | (208.48M) | (205.91M) |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.